A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2018
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms ANITSCHKOW
- Sponsors Amgen
- 17 Apr 2018 Status changed from active, no longer recruiting to completed.
- 20 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Oct 2017 Planned End Date changed from 20 Feb 2018 to 6 Apr 2018.